ArticleJournal of medical biochemistry2026
Paraoxonase-1 activity and AOPP levels in patients with type 2 diabetes mellitus.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paraoxonase 1 (PON1) is a calcium-dependent esterase and exerts antioxidant and antiatherogenic properties. Advanced oxidation protein products (AOPP) are a group of carbonylated protein products showing oxidant-mediated protein damage. This study aimed to determine serum PON1 activities and AOPP concentrations in diabetic patients and to evaluate these parameters in terms of their relationships with diabetes mellitus (DM) and related factors. Methods: A total of 93 patients diagnosed with type 2 DM and 30 healthy controls were enrolled in the study. Serum AOPP levels and PON1 activities were measured spectrophotometrically. Other biochemical parameters, including glucose, total cholesterol, HDL-C, LDL-C, triglycerides, HbA1c and clinical/demographic data, were measured in the routine blood chemistry laboratory and retrieved from patient files. Results: Serum PON1 activity was significantly lower in patients with DM (31.6 [21.49-48.45] U/mL) compared to controls (41.08 [29.07-54.35] U/mL) (p= 0.028). Serum AOPP concentration was significantly higher in diabetic patients (584.6 [453.8-778.6] pmol/L) than in controls (173.9 [98.77-224.1] pmol/L) (p< 0.001). PON1 activity negatively correlated with AOPP concentration and positively with serum HDL-1 levels. AOPP concentration positively correlated with age, weight, HbA1c, glucose, total cholesterol, and LDL-C. A PON1 activity cut-off of ^25 U/mL predicted DM with a sensitivity of 36.56% and specificity of 90% (AUC: 0.634, p= 0.028). An AOPP concentration cut-off of >340 mmol/L predicted DM with a sensitivity of 89.25% and specificity of 93.33% (AUC: 0.965). Both PON1 (OR: 10.821, 95% CI: 1.959-59.778, p= 0.006) and AOPP (OR: 190.068, 95% CI: 20.102-1797.148, p< 0.001) were independently associated with DM after adjusting for age, sex, and weight. Conclusions: AOPP and PON1 may play a significant role in the development and progression of DM. In particular, serum AOPP concentrations appear to be distinctive among patients with new-onset DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.